Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Primary objective: To evaluate the similarity of the pharmacokinetic characteristics of a single subcutaneous injection of 0.25 mg of the investigational drug (T) semaglutide injection (provided by Yichang Renfu Pharmaceutical Co., Ltd., specification: 1.34 mg/ml, 1.5 ml) and 0.25 mg of the reference drug (R) semaglutide injection (produced by Novo Nordisk A/S, trade name: Novotec, specification: 1.34 mg/ mL, 1.5 ml) in healthy adult subjects under fasting conditions. Secondary objective: To evaluate the immunogenicity and safety of the investigational drug semaglutide injection and the reference drug (Novotec) in healthy adult subjects.

(1) To verify the effectiveness of eptifibatide for injection in percutaneous coronary intervention in high-risk ACS patients (2) To verify the safety of eptifibatide for injection in percutaneous coronary intervention in high-risk ACS patients

Evaluate the pharmacokinetic and pharmacodynamic characteristics of eptifibatide for injection in healthy humans, obtain pharmacodynamic and pharmacokinetic data, and establish a PK/PD model to provide a basis for guiding clinical medication.